4 completed. 4 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 4 |
| Phase 3 | 1 | Completed 1 |
Follow Craving: new trials by email Literature Review of Craving trials Research Report on Craving
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| An Inflammatory Challenge Using Endotoxin Placebo, Endotoxin - Alcohol Use Disorder, Inflammatory Response | Phase 2 | Completed | University of California, Los Angeles | 20 | 2021-10-19 | 2025-05-01 |
| The Efficacy of Suvorexant in Treatment of Patients With Substance Use Disorder and Insomnia: A Pilot Open Trial Suvorexant 20 mg - Sleep Disturbance, Craving | Phase 2 / Phase 3 | Completed | Milton S. Hershey Medical Center | 28 | 2019-07-01 | 2024-02-13 |
| The Impact of Ashwagandha on Perceived Stress, Sleep and Food Cravings in College Students Ashwagandha, Placebo - Stress, Sleep | Phase 2 | Completed | University of Colorado, Colorado Springs | 60 | 2019-05-29 | 2022-06-24 |
| Smoking Cessation Facilitated by Glucagon-like Peptide-1 (GLP-1) Analogues Dulaglutide, 0.5 ml normal saline (0.9% sodium chloride [0.9% NaCl]) - Glucagon-like Peptide-1, Smoking Cessation | Phase 2 | Completed | University Hospital, Basel, Switzerland | 256 | 2017-06-26 | 2022-09-13 |
Alcoholism (1) · Body Weight Changes (1) · Consciousness Disorders (1) · Parasomnias (1) · Smoking Cessation (1)
Mental Disorders (2) · Nervous System Diseases (2) · Pathological Conditions, Signs and Symptoms (2) · Signs and Symptoms (2) · Alcohol-Related Disorders (1) · Behavior (1) · Body Weight (1) · Chemically-Induced Disorders (1) · Health Behavior (1) · Neurobehavioral Manifestations (1) · Neurocognitive Disorders (1) · Neurologic Manifestations (1) · Sleep Wake Disorders (1) · Substance-Related Disorders (1)
Sodium Chloride (2) · Ashwagandha (1) · Endotoxins (1) · Glycerol (1) · Saline Solution (1) · dulaglutide (1) · suvorexant (1)
Milton S. Hershey Medical Center (1) · University Hospital, Basel, Switzerland (1) · University of California, Los Angeles (1) · University of Colorado, Colorado Springs (1)
United States (3) · Switzerland (1)
Bettina Winzeler, Dr. (1) · Lara Ray, PhD (1) · Margaret Harris, PhD (1) · Venkatesh Basappa Krishnamurthy, MD (1)
PMID 35984870, PMID 35984871, PMID 36874396, PMID 37081574, PMID 37991022, PMID 38264360, PMID 38371479, PMID 40037282
2017 (1)